PLEASANTON, Calif., Nov. 1, 2024 /PRNewswire/ — DermRays is excited to announce a groundbreaking addition to its product line aimed specifically at male users. Set to launch in the summer of 2025, the new men’s hair removal device will feature an entirely new design and upgraded functionalities tailored to meet the unique grooming needs of men. This innovative product reflects DermRays’ commitment to enhancing user experience and providing effective solutions for a diverse customer base.
As more men express interest in hair removal, DermRays has taken proactive steps based on customer feedback to develop this cutting-edge device. This decision marks a significant breakthrough in the at-home laser hair removal market, ensuring that men can achieve salon-quality results in the comfort of their own homes.
In addition to this exciting news, DermRays is also currently running a Thanksgiving promotion from November 1-10th, 2024, offering $120 OFF sitewide. This special event allows customers to explore the range of DermRays products while enjoying substantial savings.
Stay tuned for further updates on the upcoming men’s hair removal device, and don’t miss out on the Thanksgiving promotion, where you can take advantage of these incredible offers and start your journey toward smoother skin. DermRays remains dedicated to innovation and customer satisfaction, setting the standard for effective, at-home laser hair removal solutions.
Media Contact:
Facebook: @dermraysofficial
Instagram: @dermrays_global
YouTube: @DermRays
TikTok: @dermrays.official
Email: [email protected]
ข่าวที่เกี่ยวข้อง
- World Young Scientist Summit 2026 Opens in Wenzhou, Zhejiang
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
